TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02752386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: Participants will received biofeedback training to reduce arousal and pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Training
Description: Participants will received biofeedback training to reduce arousal and pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Training
Description: Participants will received biofeedback training to reduce arousal and pain
Study: NCT01717937

Intervention type: PROCEDURE
Intervention: Phase variance optical coherence tomography (PV-OCT)
Description: Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
Study: NCT03498924

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of biomarkers in serum and endometrial tissue
Description: Blood sample and endometrial sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of biomarkers in serum and endometrial tissue
Description: Blood sample and endometrial sample
Study: NCT03111381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: IV toradol
Study: NCT04570176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adrenalectomy for adrenal adenoma
Description: adrenalectomy， cystectomy and nephrectomy
Study: NCT01601691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DuraSeal
Description: Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
Study: NCT04310254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EDTA and CHX Solution
Description: The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EDTA Solution
Description: The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
Study: NCT04122534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Mindfulness Training
Description: Educational and experiential training to reduce occupational-based secondary trauma.
Study: NCT04310254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CHX Solution
Description: The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
Study: NCT00402025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
Study: NCT01770002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Everted suture technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-everted suture technique
Study: NCT03237117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Description: to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone (GH)
Description: to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
Study: NCT03699033

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2.5 Gy/fraction
Description: Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation.
Study: NCT03858023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
Study: NCT03380416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portfolio Diet
Description: Medium-term (8 weeks ) nutritional intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MUFA Diet
Description: Medium-term (8 weeks ) nutritional intervention used as control
Study: NCT01632163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form:solution~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution~Route of administration: subcutaneous injection
Study: NCT03186716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
Study: NCT04481841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oryzanol + vitamin B2 (riboflavin) + vitamin E
Description: 1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oryzanol + vitamin B2 (riboflavin) + vitamin E
Description: 1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.
Study: NCT05327712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: No outreach during the intervention period beyond an initial eligibility notice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email only
Description: Email reminders in addition to an initial eligibility notice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone only
Description: Phone call offering enrollment assistance in addition to an initial eligibility notice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone and email
Description: Phone call and email reminders in addition to an initial eligibility notice.
Study: NCT02464241

Intervention type: OTHER
Intervention: only examination
Study: NCT02194140

Intervention type: OTHER
Group type: OTHER
Intervention: oral iodinated contrast material
Description: diluted in water
Study: NCT01433887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 48-weeks course
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 48-weeks course
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Study: NCT03283163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Testing and Training
Description: The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
Study: NCT01351077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA DevScreen Module
Description: This module assists in the diagnosis and management of developmental screening
Study: NCT02772887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: amino acid supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03528707

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter-Omega
Description: Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
Study: NCT01433887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
Study: NCT03464201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40 MG
Description: Enzalutamide 160 mg p.o. every day
Study: NCT00035555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Solution, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Solution, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
Study: NCT03690167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor (CGF)
Description: CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Platelet Rich Fibrin (A-PRF)
Description: A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Nothing applied after extraction
Study: NCT04234061

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ibrutinib and Tisagenlecleucel
Description: Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
Study: NCT00644189

Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
Study: NCT00685750

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment
Study: NCT03990987

Intervention type: OTHER
Intervention: time of receiving operation
Description: patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance

Intervention type: OTHER
Intervention: time of receiving operation
Description: patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
Study: NCT00685750

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of tumor and blood samples
Description: Samples will be collected before and after standard treatment
Study: NCT05025631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
Study: NCT01485471

Intervention type: DEVICE
Intervention: Diffuse optical spectroscopy imaging
Description: ear exam imaging
Study: NCT01142141

Intervention type: OTHER
Group type: OTHER
Intervention: manual therapy, kinesiotherapy
Study: NCT04048031

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrafol Supplement Capsules
Description: NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrafol Supplement Capsules
Description: NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
Study: NCT03584217

Intervention type: DRUG
Group type: OTHER
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study: NCT03088033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD System II implant
Description: The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Description: intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
Study: NCT03213951

Intervention type: OTHER
Intervention: Experimental beta probe
Description: 3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.

Intervention type: DIAGNOSTIC_TEST
Intervention: PSMA-PET
Description: PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
Study: NCT01003327

Intervention type: DEVICE
Group type: OTHER
Intervention: I-gel
Description: intubation with I-gel airway

Intervention type: DEVICE
Group type: OTHER
Intervention: LMA-Unique
Description: LMA-Unique airway is inserted first, then the I-gel
Study: NCT04366531

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: START-VET
Description: prison reentry program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: This intervention involves no additional services above what is provided by the local health care system
Study: NCT02999659

Intervention type: DEVICE
Intervention: Pupilometer
Description: Device to measure change in pupil diameter due to a defined light stimulus.

Intervention type: DEVICE
Intervention: Pupilometer
Description: Device to measure change in pupil diameter due to a defined light stimulus.
Study: NCT02928835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee flexion Dynasplint orthosis
Description: Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
Study: NCT03777020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Service Dog Training Program
Description: Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.

Intervention type: OTHER
Group type: OTHER
Intervention: Dog Training Education
Description: Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.